Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Cancer care provider Proton Partners International booked a deeper annual loss costs establishing a treatment network far outweighed a rise in sales.
Pre-tax losses for the year through February amounted to £21.5m, compared to losses of £11.5m on-year.
Revenue grew to £1.5m, up from a nominal £18k on-year.
'In 2018, we set out the critical capability we needed to position us as the most advanced cancer network in the UK and we have made good progress, particularly with our focus on precision radiotherapy,' chief executive Mike Moran said.
'We have treated 27 patients with proton beam therapy and demand is increasing.'
'With three Rutherford Cancer Centres now operational and a fourth under construction we are well placed to increase patient access and choice - which is at the core of our business.'